Sarcoma Comprehensive NGS Fusion Panel
Also known as: NGS Comprehensive Sarcoma Fusion Profile
Use
The Sarcoma Comprehensive NGS Fusion Panel is an RNA-based sequencing test designed to detect translocations and fusions involving a variety of genes associated with sarcoma. It can identify known and novel fusion partners, aiding in the diagnosis and characterization of sarcomas, which may help guide appropriate treatment strategies.
Special Instructions
As of May 12, 2025, this test replaces several other panels: Ewing Sarcoma NGS Fusion Panel, NeoTYPE® Liposarcoma Fusion Profile, Non-Ewing Sarcoma NGS Fusion Panel, and Rhabdomyosarcoma NGS Fusion Panel.
Limitations
While this panel can detect a wide range of translocations and fusions, limitations may exist regarding the detection of very low abundance RNA or fusion events not covered by the genes listed in the panel. The results are dependent on the quality of the RNA extracted and the completeness of the gene coverage offered by the panel.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
21 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Paraffin block or 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns
Collection Instructions
Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Storage Instructions
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. NYS clients please provide date and time of Collection.